CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
erlotinib hydrochloride +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01259089
NCT01259089Phase 2Completed
CompareCT.gov

A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors

Northwestern University·interventional·Posted Dec 13, 2010·Updated Sep 11, 2019

In Brief

A Phase 2 clinical trial evaluating erlotinib hydrochloride, Hsp90 inhibitor AUY922, and 4 other interventions for Adenocarcinoma of the Lung and Non-small Cell Lung Cancer. Completed, enrolled 38 participants across 2 sites.

Detailed Summary

Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Lung, Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsRobert H. Lurie Cancer Center

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 13, 2010
Enrollment StartApr 27, 2011
Primary CompletionJun 4, 2013
Study CompletionSep 29, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.6 years ago

Interventions

erlotinib hydrochloridedrug

Given orally

Hsp90 inhibitor AUY922drug

Given IV

laboratory biomarker analysisother

Correlative studies

needle biopsyprocedure

Undergo image-guided needle biopsy (correlative studies)

mutation analysisgenetic

Correlative studies

pharmacological studyother

Correlative studies